Trade war with China? Check. Cuts to scientific research? Check.

At a launch event on Feb. 20, Roche detailed plans to enter Illumina's sequencing stronghold with a new platform. Roche's platform is in testing now and scheduled to launch commercially in 2026.

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

RBC Capital reiterated an Outperform rating and $247 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about its sequencing by extension technology, with initial ...

Illumina is raising the curtain on its upcoming entry into spatial transcriptomics, with tech designed to help researchers explore cellular behavior mapped across complex tissues. The announcement ...

BEIJING’S surprise move to blacklist Illumina has unleashed a frenzy among the US firm’s Chinese rivals to win market share from the gene-sequencing giant. While Illumina is still assessing the ...

In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against other top AI stocks buzzing on latest news. Investors are continuing to assess the impact of new ...

Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity.

Illumina and next-gen sequencing (NGS) are synonymous. But to anyone paying attention, the company’s recent emphasis on multiomics has been hard to miss. Indeed, the company has launched both ...